Contemporary clinical investigations have established that the combination of gemcitabine plus cisplatin with PD-L1 inhibitors exhibits promising therapeutic efficacy in patients with advanced biliary tract cancer [69]. The gene discussed is CD274; the disease is biliary tract neoplasm.